For long Epstein–Barr virus (EBV) has been suspected to be involved in the pathogenesis of systemic lupus erythematosus (SLE). The aim of this study was to verify the association between EBV, cell-free DNA (cfDNA) and kidney disease in SLE.
Methods
Blood samples were obtained from 43 SLE patients and 50 healthy individuals. EBV load was measured via real-time PCR assay. Sizing and quantification of plasma cfDNA was performed on Bioanalyzer. We proposed that the uniformity of cfDNA fragmentation can be described using cfDNA fragmentation index.
Results
SLE patients with chronic kidney disease (CKD +) had higher EBV load compared to CKD(–) patients (P = 0.042). Patients with high cfDNA level had higher EBV load (P = 0.041) and higher cfDNA fragmentation index (P < 0.001) compared to patients with low cfDNA level. Among patients with high cfDNA level, EBV load was higher in CKD(+) group compared to CKD(–) group (P = 0.035). EBV load was positively correlated with the fragmentation index in all SLE patients (P = 0.028, R2 = 0.13), and the correlation was even more pronounced in CKD (+) patients (P < 0.001, R2 = 0.20).
Conclusions
We showed that EBV load was associated with non-uniform cfDNA fragmentation, higher cfDNA levels, and kidney disease in SLE patients. Although the causality of this relationship could not be determined with the current study, it brings rationale for further investigations on the role of EBV and cfDNA interplay in SLE pathogenesis.
PenderMPCsurhesPASmithC, et al.
Epstein-Barr virus-specific adoptive immunotherapy for progressive multiple sclerosis. Mult Scler2014;
20: 1541–1544.
2.
PenderMPCsurhesPASmithC, et al.
Epstein-Barr virus-specific T cell therapy for progressive multiple sclerosis. JCI Insight2020;
5: e144624.
3.
SerafiniBRosicarelliBFranciottaD, et al.
Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain. J Exp Med2007;
204: 2899–2912.
4.
CroiaCAstorriEMurray-BrownW, et al.
Implication of Epstein-Barr virus infection in disease-specific autoreactive B cell activation in ectopic lymphoid structures of Sjögren's syndrome. Arthritis Rheumatol2014;
66: 2545–2557.
5.
BertsiasGCerveraRBoumpasDT.Systemic lupus erythematosus: pathogenesis and clinical features. In: BijlsmaJWJHachullaE (eds) Eular textbook on rheumatic diseases.
London:
BMJ group, 2012, pp.476–505.
6.
MunzCLunemannJDGettsMTMillerSD.Antiviral immune responses: triggers of or triggered by autoimmunity?Nat Rev Immunol2009;
9: 246–258.
7.
LiZ-XZengSWuH-XZhouY.The risk of systemic lupus erythematosus associated with Epstein–Barr virus infection: a systematic review and meta-analysis. Clin Exp Med2019;
19: 23–36.
8.
HarleyJBChenXPujatoM, et al.
Transcription factors operate across disease loci, with EBNA2 implicated in autoimmunity. Nat Genet2018;
50: 699–707.
9.
HanlonPAvenellAAucottLVickersMA.Systematic review and meta-analysis of the sero-epidemiological association between Epstein-Barr virus and systemic lupus erythematosus. Arthritis Res Ther2014;
16: R3.
10.
MoonUYParkSJOhST, et al.
Patients with systemic lupus erythematosus have abnormally elevated Epstein–Barr virus load in blood. Arthritis Res Ther2004;
6: R295–R302.
11.
YuXXYaoCWTaoJL, et al.
The expression of renal Epstein-Barr virus markers in patients with lupus nephritis. Exp Ther Med2014;
7: 1135–1140.
12.
DingYHeXLiaoWYiZYangHXiangW.The expression of EBV-encoded LMP1 in young patients with lupus nephritis. Int J Clin Exp Med2015;
8: 6073–6078.
13.
ZakiMEAbou El-KhierNTAl-KasabyNMAbdelsalamMNassarMKAbdelwahabAM.Epstein Barr virus in patients with nephropathy associated with systemic lupus erythematous, pilot study in Egyptian patients. Egypt J Immunol2018;
25: 1–8.
14.
FitzsimmonsLKellyGL.EBV and apoptosis: the viral master regulator of cell fate?Viruses2017;
9: 339.
15.
YadavPTranHEbegbeR, et al.
Antibodies elicited in response to EBNA-1 may cross-react with dsDNA. PLoS One2011;
6: e14488.
16.
PadalkoEYBossuytX.Anti-dsDNA antibodies associated with acute EBV infection in Sjögren's syndrome. Ann Rheum Dis2001;
60: 992.
17.
YungSChanTM.Mechanisms of kidney injury in lupus nephritis – the role of anti-dsDNA antibodies. Front Immunol2015;
6: 475.
18.
DuvvuriBLoodC.Cell-Free DNA as a biomarker in autoimmune rheumatic diseases. Front Immunol2019;
10: 502.
19.
MeansTKLatzEHayashiFMuraliMRGolenbockDTLusterAD.Human lupus autoantibody-DNA complexes activate DCs through cooperation of CD32 and TLR9. J Clin Invest2005;
115: 407–417.
20.
MossJMagenheimJNeimanD, et al.
Comprehensive human cell-type methylation atlas reveals origins of circulating cell-free DNA in health and disease. Nat Commun2018;
9: 5068.
21.
StrounMLyauteyJLederreyCOlson-SandAAnkerP.About the possible origin and mechanism of circulating DNA apoptosis and active DNA release. Clin Chim Acta2001;
313: 139–142.
22.
van der VaartMPretoriusPJ.Circulating DNA. Its origin and fluctuation. Ann N Y Acad Sci2008;
1137: 18–26.
23.
SalemmeRPeraltaLNMekaSHPushpanathanNAlexanderJJ.The role of NETosis in systemic lupus erythematosus. J Cell Immunol2019;
1: 33–42.
24.
ZhangSLuXShuX, et al.
Elevated plasma cfDNA may be associated with active lupus nephritis and partially attributed to abnormal regulation of neutrophil extracellular traps (NETs) in patients with systemic lupus erythematosus. Intern Med2014;
53: 2763–2771.
25.
VillanuevaEYalavarthiSBerthierCC, et al.
Netting neutrophils induce endothelial damage, infiltrate tissues, and expose immunostimulatory molecules in systemic lupus erythematosus.J Immunol2011;
187: 538–552.
26.
BrooksWH.Increased polyamines alter chromatin and stabilize autoantigens in autoimmune diseases. Front Immunol2013;
4: 91.
27.
McCollSRRobergeCJLarochelleBGosselinJ.EBV induces the production and release of IL-8 and macrophage inflammatory protein-1 alpha in human neutrophils. J Immunol1997;
159: 6164–6168.
28.
Mccoubrey-HoyerAOkarmaTBHolmanHR.Partial purification and characterization of plasma DNA and its relation to disease activity in systemic lupus erythematosus. Am J Med1984;
77: 23–34.
29.
ChenJAMeisterSUrbonaviciuteV, et al.
Sensitive detection of plasma/serum DNA in patients with systemic lupus erythematosus. Autoimmunity2007;
40: 307–310.
30.
AtamaniukJHsiaoYYMustakM, et al.
Analyzing cell-free plasma DNA and SLE disease activity. Eur J Clin Invest2011;
41: 579–583.
31.
CepikaAMSoldo JurešaDMorović VerglesJ, et al.
Decrease in circulating DNA, IL-10 and BAFF levels in newly-diagnosed SLE patients after corticosteroid and chloroquine treatment. Cell Immunol2012;
276: 196–203.
32.
TugSHelmigSMenkeJ, et al.
Correlation between cell free DNA levels and medical evaluation of disease progression in systemic lupus erythematosus patients. Cell Immunol2014;
292: 32–39.
33.
HendyOMMotalibTAEl ShafieMA, et al.
Circulating cell free DNA as a predictor of systemic lupus erythematosus severity and monitoring of therapy. Eur J Med Genet2016;
17: 79–85.
34.
XuYSongYChangJ, et al.
High levels of circulating cell-free DNA are a biomarker of active SLE. Eur J Clin Invest2018;
48: e13015.
35.
TruszewskaAForoncewiczBPączekL.The role and diagnostic value of cell-free DNA in systemic lupus erythematosus. Clin Exp Rheumatol2017;
35: 330–336.
36.
TruszewskaAWirkowskaAGalaK, et al. Cell-free DNA profiling in patients with systemic lupus erythematosus. Lupus 2020; 29: 1759–1772. doi: 10.1177/0961203320957717
37.
WeeningJJD'AgatiVDSchwartzMM, et al.
The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol2004;
15: 241–250.
38.
GroupKW.Chapter 1: definition and classification of CKD. Kidney Int Suppl2011;
3: 19–62.
GladmanDGinzlerEGoldsmithC, et al.
The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum1996;
39: 363–369.
41.
GandhiMKLambleyEBurrowsJ, et al.
Plasma Epstein-Barr virus (EBV) DNA is a biomarker for EBV-positive Hodgkin's lymphoma. Clin Cancer Res2006;
12: 460–464.
42.
MayerHBWankeCAWilliamsM, et al.
Epstein-Barr virus-induced infectious mononucleosis complicated by acute renal failure: case report and review. Clin Infect Dis1996;
22: 1009–1018.
43.
MorettiMLavaSAGZgraggenL, et al.
Acute kidney injury in symptomatic primary Epstein-Barr virus infectious mononucleosis: systematic review. J Clin Virol2017;
91: 12–17.
44.
BeckerJLMillerFNuovoGJJosepovitzCSchubachWHNordEP.Epstein-Barr virus infection of renal proximal tubule cells: possible role in chronic interstitial nephritis. J Clin Invest1999;
104: 1673–1681.
45.
JohKKanetsunaYIshikawaY, at al.
Epstein-Barr virus genome-positive tubulointerstitial nephritis associated with immune complex-mediated glomerulonephritis in chronic active EB virus infection. Virchows Arch1998;
432: 567–573.
46.
KanoKYamadaYSatoYArisakaOOnoYUedaY.Glomerulonephritis in a patient with chronic active Epstein-Barr virus infection. Pediatr Nephrol2005;
20: 89–92.
47.
OkadaHIkedaNKobayashiT, et al.
An atypical pattern of Epstein-Barr virus infection in a case with idiopathic tubulointerstitial nephritis. Nephron2002;
92: 440–444.
48.
CelecPVlkováBLaukováLBábíčkováJBoorP.Cell-free DNA: the role in pathophysiology and as a biomarker in kidney diseases. Expert Rev Mol Med2018; 20: e1.
49.
CarlsonJAHodderSRUcciAAMadaioMP.Glomerular localization of circulating single-stranded DNA in mice. Dependence on the molecular weight of DNA. J Autoimmun1988;
1: 231–241.
